Novel CAR-T therapy Shows Promising Results in Treating Cancer | Current Affairs | Vision IAS
News Today Logo

Novel CAR-T therapy Shows Promising Results in Treating Cancer

Posted 02 May 2025

1 min read

Developed by Brazilian scientists, HSP-CAR30 therapy targets the CD30 protein and has successfully completed its initial trial. 

  • CD30 protein is found on some T cells and B cells (two types of white blood cells). It helps in cancer diagnosis and treatment planning. 
    • T-cells are special cells whose primary function is cytotoxic, meaning killing other cells.

Key Developments

  • Higher Efficacy: It has 100% overall response rate and 50% of patients achieved complete remission. 
  • Safety and immunity: It has no dose-limiting toxicities, and CAR30+ cells remained detectable in 60% of evaluable patients even a year after infusion.

What is Chimeric Antigen Receptor T-cell (CAR-T) Therapy?

  • Chimeric Antigen Receptor T-cell (CAR-T) therapy is a type of treatment where a patient's T cells (a kind of white blood cell) are collected from the blood and genetically modified in a laboratory. 
  • A special receptor called CAR (Chimeric Antigen Receptor) is added to these T cells, enabling them to recognize and attack cancer cells more effectively.
  • CAR-T therapy has already shown significant success in treating blood cancers, including Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, and Multiple Myeloma.
  • Tags :
  • Cancer
  • Chimeric Antigen Receptor T-cell (CAR-T) Therapy
  • HSP-CAR30
  • T-Cells
Watch News Today
Subscribe for Premium Features